Matrixyl (Palmitoyl Pentapeptide-4)
Overview
Matrixyl is a synthetic matrikine — the pentapeptide KTTKS, taken from a fragment of type I procollagen, joined to a palmitic-acid (C16) chain that improves its affinity for skin lipids. The peptide portion is investigated as a signal that tells fibroblasts to rebuild extracellular matrix, while the fatty-acid tail is a formulation strategy for topical penetration. It is one of the most widely used cosmetic signal peptides in collagen and firmness research.
Chemical Profile
| Property | Value |
|---|---|
| CAS number | 214047-00-4 |
| INCI name | Palmitoyl Pentapeptide-4 |
| Amino-acid sequence | Pal-Lys-Thr-Thr-Lys-Ser-OH |
| One-letter code | Pal-KTTKS |
| Molecular formula | C₃₉H₇₅N₇O₁₀ |
| Molecular weight | 802.06 g/mol |
| Purity (HPLC) | ≥ 98% |
| Appearance | White to off-white lyophilized powder |
- Class
- Palmitoylated matrikine signal peptide
- Origin
- Fragment of type I procollagen (KTTKS)
- Research status
- Extensive clinical research
- Typical route
- Topical
- Reference trade name
- Matrixyl™ (Sederma)
- Key feature
- Mimics collagen breakdown to signal new synthesis
Mechanism of Action
Matrixyl works on the matrikine principle: a small fragment of a matrix protein acts as a message to cells about the condition of the surrounding tissue. The KTTKS sequence is a piece of procollagen, so fibroblasts read it as a cue that collagen has broken down and respond by producing fresh matrix. The palmitoyl chain does not carry biological signal itself — it improves how the molecule associates with skin lipids in topical systems.
| Pathway | Research description |
|---|---|
| Collagen synthesis | Studied for upregulation of procollagen I and III expression in dermal-fibroblast models. |
| Fibroblast signalling | Investigated as a matrikine acting through fibroblast receptors, discussed alongside TGF-β signalling. |
| Feedback amplification | Framed as a positive loop — new collagen is partially processed into further matrikine fragments. |
| Wider ECM | Associated in models with fibronectin, elastin and glycosaminoglycan synthesis. |
| MMP balance | Explored in relation to the balance between matrix metalloproteinases (MMP-1) and their inhibitors (TIMP-1). |
Tissue-level effects reported in the literature (research context, not product claims):
| Tissue | Studied mechanism | Reported direction |
|---|---|---|
| Dermis | Fibroblast activation + collagen neosynthesis | Increased firmness/elasticity in models |
| Dermal–epidermal junction | Collagen VII and laminin expression | Improved structural support in models |
| Extracellular matrix | GAG and proteoglycan deposition | Improved hydration/plumpness in models |
Pharmacology
| Parameter | Value |
|---|---|
| logP | 3.8 (lipophilic — raised by palmitoylation) |
| pKa | ≈ 10.5 (lysine ε-amino groups) |
| Topical bioavailability | ~5–8% with the palmitoyl conjugate |
| Stability | High — the palmitoyl group shields against exopeptidases |
| Protein binding | High (albumin, dermal proteins) |
| Metabolism | Partial proteolytic breakdown in the epidermis |
| Route of administration | Topical |
Research Evidence
Matrixyl is a reference compound in cosmetic-peptide research and is frequently used as a comparator for newer matrikines, with both cell-based (preclinical) and human (clinical) studies. The directions and study types below describe where it appears in the literature.
Collagen & firmness
A benchmark peptide in collagen-stimulation and skin-firmness research in fibroblast and explant models.
Expression-line studies
Studied in anti-aging formulation research, often paired with neuromodulatory peptides.
Delivery research
Used to compare palmitoylated versus unmodified peptide penetration in topical systems.
Matrikine biology
A model system for studying how procollagen fragments feed back on matrix synthesis.
Preclinical research — representative models and what they investigate:
| Model | Research focus | Reference |
|---|---|---|
| Human dermal fibroblasts | Procollagen I / III expression | Katayama K, et al. (1993) |
| Fibroblast cultures | Elastin, fibronectin and GAG synthesis | Lintner K (review) |
| Human skin explants | Dermal thickness and collagen density | Gorouhi F, Maibach HI (2009) |
Clinical research — the types of human study in which the ingredient is examined:
| Study type | Endpoints studied | Reference |
|---|---|---|
| Topical palmitoyl-pentapeptide cream | Photoaged facial skin, wrinkle appearance | Robinson LR, et al. (2005) |
| Anti-aging formulations | Skin firmness and fine-line appearance | Lupo MP, Cole AL (2007) |
Representative reported directions from the literature (qualitative; GLP-1 entries reflect published clinical-trial results, others are reported study directions, not restated as precise product claims):
| Reported direction / finding | Context | Reference |
|---|---|---|
| Upregulates procollagen I and III expression | human dermal fibroblasts | Katayama K et al., 1993 |
| Improvement of photoaged facial skin | topical human study | Robinson LR et al., 2005 |
For laboratory research and cosmetic formulation study only. Descriptions refer to published research contexts and are not product or health claims.
Formulation & Dosing Reference
| Parameter | Value |
|---|---|
| Typical topical concentration | 0.5–5.0% (w/w) |
| Common working range | ≈ 3% |
| Solubility in water | Poor (< 1 mg/mL) — needs a co-solvent or emulsion |
| Solubility in ethanol | Moderate (≈ 5 mg/mL) |
| Solubility in DMSO | ≥ 50 mg/mL |
| Recommended formulation pH | 5.0–7.0 |
| Storage (powder) | 2–8°C, sealed, dry, protected from light |
- Because the peptide is poorly water-soluble, it is usually formulated in an oil-in-water emulsion or dispersed with a co-solvent (ethanol, propylene glycol, DMSO).
- The palmitoyl amide bond is most stable near pH 5.0–7.0; strongly acidic or basic conditions accelerate hydrolysis.
Safety Profile
| Assessment | Reported result |
|---|---|
| Acute oral toxicity (rat) | LD50 > 2000 mg/kg |
| Dermal irritation (rabbit) | Non-irritant at 5% |
| Ocular irritation (rabbit) | Mild at concentrated solution |
| Skin sensitization (GPMT) | Non-sensitizing |
| Mutagenicity (Ames) | Negative |
| INCI status | Approved cosmetic ingredient (Palmitoyl Pentapeptide-4) |
Physicochemical Properties
| Property | Value |
|---|---|
| Appearance | White to off-white lyophilized powder |
| Solubility in water | < 1 mg/mL (co-solvent or emulsion required) |
| Solubility in ethanol | ≈ 5 mg/mL |
| Solubility in DMSO | ≥ 50 mg/mL |
| Melting point | ≈ 180°C (decomposition) |
| pH (1% suspension) | 5.0–6.5 |
| Fatty-acid modifier | Palmitic acid (C16:0) |
| Character | Amphiphilic (lipophilic tail + hydrophilic peptide) |
Synthesis & Manufacturing
Matrixyl is made by solid-phase peptide synthesis of the KTTKS pentapeptide, followed by attachment of palmitic acid to the N-terminus. The palmitoyl group changes the molecule’s behaviour on reversed-phase columns, so purification uses a high-organic gradient.
| Step | Detail |
|---|---|
| Strategy | Solid-phase peptide synthesis, Fmoc/tBu chemistry |
| Resin | Wang resin (C-terminal acid) |
| Coupling | HATU / HBTU with DIPEA |
| Side-chain protection | Lys(Boc), Thr(tBu), Ser(tBu) |
| Palmitoylation | Palmitic acid coupled to the N-terminus after final Fmoc removal |
| Cleavage | TFA / TIPS / H₂O (95 : 2.5 : 2.5) |
| Purification | Preparative RP-HPLC (C18, high-organic 60–90% gradient) |
- The amphiphilic Pal-KTTKS retains strongly on C18, so a high acetonitrile gradient is needed to elute it cleanly.
- A key quality attribute is that palmitoylation occurs at the N-terminus (not on a lysine side chain), confirmed by MS fragmentation.
Analytical Methods
| Method | Purpose | Typical result |
|---|---|---|
| RP-HPLC (C18, UV 214 nm) | Purity | ≥ 98% |
| ESI-MS (positive mode) | Identity / mass | m/z consistent with the palmitoyl pentapeptide |
| MALDI-TOF | Mass confirmation | [M+Na]⁺ consistent with the palmitoyl pentapeptide |
| Amino-acid analysis | Composition | Thr : Lys : Ser = 2 : 2 : 1 |
| LC-MS/MS | Palmitoylation site | N-terminal palmitoylation confirmed |
| Karl Fischer | Water content | < 5% |
| TGA | Decomposition temperature | ≈ 180°C |
Representative RP-HPLC purity method (the palmitoyl chain needs a high-organic gradient):
- Column: C18, 5 µm, 250 × 4.6 mm
- Mobile phase A: 0.1% TFA in water · Mobile phase B: 0.1% TFA in acetonitrile
- Gradient: 60–90% B over ~20 min · Flow rate: 1.0 mL/min
- Detection: UV 214 nm
Stability Data
The palmitoyl group gives Matrixyl good resistance to peptidases, so it is stable as a powder and in finished emulsions; the main variables are pH and the need for emulsification.
| Condition | Duration | Result |
|---|---|---|
| Lyophilized powder, 2–8°C, dark | ≥ 24 months | No significant degradation |
| Lyophilized powder, 25°C, dark | ≥ 12 months | Minimal degradation |
| Aqueous solution, pH 5.5, 4°C, dark | ≈ 7 days | Minor degradation |
| Formulated O/W emulsion, 25°C | 12+ months | Peptide largely retained |
| Light exposure (ICH Q1B) | Standard | Light-stable |
| Freeze–thaw (−20°C ⇄ 25°C) | 3 cycles | Acceptable |
- The N-terminal palmitoyl group protects against exopeptidase cleavage, which is the main reason for the excellent stability.
- An emulsion or co-solvent (ethanol, DMSO, propylene glycol) is needed for aqueous systems; stability is best in oil-in-water emulsions.
- Optimal pH is 5.0–7.0 — the palmitoyl amide bond hydrolyses faster in strongly acidic or basic conditions.
Selected References
Representative peer-reviewed literature on KTTKS / Palmitoyl Pentapeptide-4. Listed for research reference.
- Katayama K, et al. A pentapeptide from type I procollagen promotes extracellular matrix production. Journal of Biological Chemistry, 1993.
- Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin-care product. International Journal of Cosmetic Science.
- Robinson LR, et al. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. International Journal of Cosmetic Science, 2005.
- Gorouhi F, Maibach HI. Role of topical peptides in preventing or treating aged skin. International Journal of Cosmetic Science, 2009.
- Lupo MP, Cole AL. Cosmeceutical peptides. Dermatologic Therapy, 2007.
Quality & Supply
- HPLC ≥ 98% purity with a Certificate of Analysis per batch
- Identity confirmed by LC-MS; N-terminal palmitoylation verified
- Research samples through to bulk, with worldwide delivery
- Custom sequences and packaging on request
Need Matrixyl — sample or bulk?
HPLC-verified, COA per batch. Tell us the quantity you need.
